CV Sciences Stock Forecast, Price & News

-0.01 (-2.84 %)
(As of 06/18/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume310,500 shs
Average Volume937,132 shs
Market Capitalization$41.34 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CV Sciences logo

About CV Sciences

CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.25 out of 5 stars

Medical Sector

916th out of 2,101 stocks

Pharmaceutical Preparations Industry

444th out of 831 stocks

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

Is CV Sciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CV Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares.
View analyst ratings for CV Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than CV Sciences?

Wall Street analysts have given CV Sciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CV Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CV Sciences?

CV Sciences saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,055,300 shares, an increase of 24.8% from the May 13th total of 845,700 shares. Based on an average daily volume of 785,300 shares, the short-interest ratio is currently 1.3 days.
View CV Sciences' Short Interest

When is CV Sciences' next earnings date?

CV Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for CV Sciences

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) announced its quarterly earnings data on Wednesday, March, 17th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.07. The business earned $5.20 million during the quarter, compared to the consensus estimate of $6.71 million. CV Sciences had a negative trailing twelve-month return on equity of 125.42% and a negative net margin of 96.46%.
View CV Sciences' earnings history

How has CV Sciences' stock been impacted by Coronavirus?

CV Sciences' stock was trading at $0.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CVSI stock has decreased by 36.7% and is now trading at $0.3799.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CVSI?

4 Wall Street analysts have issued twelve-month target prices for CV Sciences' shares. Their forecasts range from $0.50 to $0.95. On average, they anticipate CV Sciences' share price to reach $0.68 in the next year. This suggests a possible upside of 77.7% from the stock's current price.
View analysts' price targets for CV Sciences
or view top-rated stocks among Wall Street analysts.

Who are CV Sciences' key executives?

CV Sciences' management team includes the following people:
  • Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 64, Pay $378.6k)
  • Mr. Joerg Grasser, Chief Financial Officer (Age 46, Pay $214.71k)
  • Dr. Douglas Jesse MacKay ND, Sr. VP of Scientific & Regulatory Affairs (Age 48, Pay $195.19k)
  • Mr. Tim Hitchman, VP of Operations
  • Mr. Stuart Tomc, Sr. VP of Human Nutrition
  • Mr. Jesse Karagianes, Sr. VP of Revenue Growth

Who are some of CV Sciences' key competitors?

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), (APHA), OrganiGram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA).

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.38.

How much money does CV Sciences make?

CV Sciences has a market capitalization of $41.34 million and generates $24.43 million in revenue each year. The company earns $-22,280,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does CV Sciences have?

CV Sciences employs 91 workers across the globe.

What is CV Sciences' official website?

The official website for CV Sciences is www.cvsciences.com.

Where are CV Sciences' headquarters?

CV Sciences is headquartered at 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected]

This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.